RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Rhea-AI Summary

RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and take questions.

Dial-in numbers, conference code 3406720, a live listen-only webcast and an archived recording will be available on the company’s investor relations website.

News Market Reaction – RXST

-2.19%

1 alert

-2.19% News Effect

On the day this news was published, RXST declined 2.19%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: February 25, 2026 Conference call time PT: 1:30 p.m. Pacific Time Conference call time ET: 4:30 p.m. Eastern Time +3 more

6 metrics

Earnings release date February 25, 2026 Q4 and full year 2025 results release after market close

Conference call time PT 1:30 p.m. Pacific Time Scheduled start time for Q4/FY 2025 earnings call

Conference call time ET 4:30 p.m. Eastern Time Scheduled start time for Q4/FY 2025 earnings call

US toll-free dial-in (800) 715-9871 Participant dial-in number for the earnings call

Alternate dial-in (646) 307-1963 Alternate participant dial-in number for the earnings call

Conference code 3406720 Access code required to join the earnings conference call

Market Reality Check

Price: $8.63 Vol: Volume 439,546 is at 0.39...

low vol

$8.63 Last Close

Volume Volume 439,546 is at 0.39x the 20-day average of 1,141,208, indicating light trading ahead of the announcement. low

Technical Shares at $8.21 are trading below the 200-day MA of $10.56, reflecting a weak intermediate trend before earnings.

Peers on Argus

RXST slipped 0.61% while peers showed mixed moves: DCTH +1.1%, BFLY +0.59%, NPCE...

RXST slipped 0.61% while peers showed mixed moves: DCTH +1.1%, BFLY +0.59%, NPCE +0.46%, SENS +3.24%, and CBLL -0.91%, pointing to stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 02	Conference presentation	Neutral	+0.8%	JP Morgan Healthcare presentation and webcast access details.
Dec 22	CFO transition	Neutral	+1.7%	Announcement of CFO transition and consulting arrangement.
Nov 20	Conference presentation	Neutral	-5.8%	Piper Sandler conference presentation scheduling and webcast info.
Nov 05	Earnings results	Negative	-7.3%	Q3 2025 results with lower revenue and wider loss but higher margins.
Oct 22	Earnings date	Neutral	-1.2%	Announcement of Q3 2025 earnings release date and call details.

Pattern Detected

Scheduling and conference announcements have typically led to modest moves, while full earnings releases have seen sharper downside reactions.

Recent Company History

Over the last few months, RxSight has mainly issued conference and corporate updates, with modest price reactions to events like J.P. Morgan and Piper Sandler presentations. An October 2025 earnings-date release saw only a small move of -1.17%. In contrast, the actual Q3 2025 earnings report on Nov 5, 2025 coincided with a larger -7.33% move. Today’s announcement of the Q4 and full‑year 2025 earnings date fits the pattern of low-impact, informational scheduling news.

Market Pulse Summary

This announcement sets the timeline for RxSight’s fourth quarter and full year 2025 results and conf...

Analysis

This announcement sets the timeline for RxSight’s fourth quarter and full year 2025 results and conference call, giving investors a clear date for the next detailed update. In light of prior Q3 2025 performance and existing regulatory filings, the key metrics to watch will be revenue trends, margins, and cash usage. The scheduled call and webcast provide the main forum for management’s commentary and any updated outlook.

Key Terms

ophthalmic, cataract surgery

2 terms

ophthalmic medical

"RxSight, Inc., an ophthalmic medical device company dedicated to providing..."

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

cataract surgery medical

"customized vision to patients following cataract surgery, will report financial..."

A surgical procedure that removes a cloudy natural lens in the eye and usually replaces it with a clear artificial lens, restoring vision much like cleaning or replacing a fogged camera lens to get a sharp picture again. It matters to investors because the procedure drives demand for medical devices, implants, surgical equipment and related services, so changes in procedure volume, technology, pricing or reimbursement can directly affect revenue and growth prospects for healthcare companies.

AI-generated analysis. Not financial advice.

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight^® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®/LAL+^®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

FAQ

When will RxSight (RXST) report Q4 and full year 2025 results?

RxSight will report Q4 and full year 2025 results after market close on February 25, 2026. According to RxSight, management will discuss the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET with webcast access on the investor site.

How can investors join the RxSight (RXST) earnings call on February 25, 2026?

Investors can join by dialing (800) 715-9871 or (646) 307-1963 and entering conference code 3406720. According to RxSight, a live listen-only webcast and an archived recording will be available via the company investor relations website.

What time is the RxSight (RXST) earnings call scheduled in Eastern Time?

The earnings call is scheduled for 4:30 p.m. Eastern Time on February 25, 2026. According to RxSight, the call begins at 1:30 p.m. Pacific Time and will be webcast in listen-only mode on the investor relations page.

Where will the RxSight (RXST) webcast and archived recording be available?

The live webcast and archived recording will be available on the company investor relations website at https://investors.rxsight.com/. According to RxSight, the archived recording will be posted shortly after the call’s completion for later access.

What is the RxSight (RXST) conference code for the February 25, 2026 call?

The conference code for the call is 3406720. According to RxSight, participants should enter this code when dialing the provided US numbers to join the February 25, 2026 post-market call.